The Decoded Journal.
Regulatory, market-sequencing, and category notes from Decoded Longevity. Published when the work — not the calendar — is ready.
- ai-in-practiceSG · MY · ID · TH · VN · PH
Glass plus Consensus plus Elicit — the accessible CDS and literature stack for practitioners outside the US NPI system.
OpenEvidence is gated to US-NPI-verified clinicians. The Glass-plus-Consensus-plus-Elicit bundle is the workable substitute for SEA and SA practitioners. A practical view on deploying it.
Last reviewed
2026-04-20
7 min
- practice-intelligenceSG · MY · ID · TH · VN · PH
Running a company on an agent stack — what we have learned operating Decoded this way.
Decoded itself runs on an agent stack across content, partner intake, regulatory monitoring, and triage. A first-person view on what works, what fails, and what the practice version of this looks like.
Last reviewed
2026-04-20
9 min
- clinical-equipment-intelligenceSG · MY · ID · TH · VN · PH
230V/50Hz, IEC 60335-2-53, and the SAHPRA Hazardous Substances Act — the equipment-import discipline practices skip and regret.
Voltage and frequency mismatch, refrigerant choice, and SAHPRA classification are the three places clinical equipment imports go wrong. A precise view on the discipline that prevents it.
Last reviewed
2026-04-20
8 min
- practitioner-toolkit-intelligenceSG · MY · ID · TH · VN · PH
The seven AI and clinical-software tools every modern longevity-aesthetic practitioner should know.
From AI scribes to biomarker platforms, the seven-tool toolkit Decoded curated from forty-plus evaluated platforms. Regional viability verified for SEA and SA.
Last reviewed
2026-04-20
9 min
- practice-intelligenceSG
Building a longevity practice in Singapore — regulatory, channel, and clinical considerations.
Singapore is the clearest setting in SEA to build a longevity practice and the most demanding on regulatory, premise, and claims discipline. A practical view of the build sequence in 2026.
Last reviewed
2026-04-18
9 min
- peptide-protocolsSG · MY · ID · TH · VN · PH
BPC-157 and the tissue-repair evidence base — what the clinical literature actually shows.
BPC-157 has built strong preclinical interest and a growing clinical literature. A precise view on what the evidence supports, where it is thin, and how practitioners are framing it inside their protocols.
Last reviewed
2026-04-18
8 min
- ai-in-practiceSG · MY · ID · TH · VN · PH
How AI is reshaping the diagnostic workflow in aesthetic and functional medicine.
AI is changing intake, imaging analysis, and protocol design across aesthetic and functional practice. A view on where the assistance is real, where it overpromises, and what to evaluate before deployment.
Last reviewed
2026-04-18
8 min
- longevity-scienceSG · MY · ID · TH · VN · PH
GLP-1 adjacencies in longevity practice — what sits inside and outside the prescription line.
GLP-1 prescribing remains physician-led. The adjacencies — protocol design, body-composition tracking, nutritional support, and follow-on supplementation — sit inside practitioner scope. A view on where each line falls in 2026.
Last reviewed
2026-04-18
7 min
- Market sequencingID
Indonesia's premium skincare market — sequencing a 2026 launch around halal, BPOM, and channel rules.
Indonesia is the largest single skincare opportunity in ASEAN and the least forgiving on dossier and channel discipline. A sequencing view for a 2026 launch.
Last reviewed
2026-04-15
7 min
- CategorySG · MY · ID · TH · VN · PH
Aesthetic-device reimbursement and out-of-pocket dynamics across SEA — the picture for 2026.
Aesthetic-device economics across the six markets are largely out-of-pocket — but the variations matter, and the 2026 movement on a small set of indications is real.
Last reviewed
2026-04-15
6 min
- CategorySG · MY · ID · TH · VN · PH
GLP-1 adjacencies in the longevity line — what is in scope for distributors in Southeast Asia.
GLP-1 medications are out of scope for non-pharmaceutical distributors. The adjacencies — supplements, devices, and protocols — are not. A view on what is responsibly in scope and what is not.
Last reviewed
2026-04-15
6 min
- RegulatorySG
Singapore HSA — the 2026 therapeutic-products updates and where the supplement-to-therapeutic line moved.
HSA's 2026 therapeutic-products guidance refines the line between supplement and therapeutic product. A view on which SKU profiles cross the line and what reclassification means.
Last reviewed
2026-04-15
7 min
- RegulatoryID
Indonesia's October 2026 halal certification expansion — what is in scope and what is not.
BPOM's halal certification regime expands materially in October 2026. A precise view of which categories enter scope, which carry exemptions, and what brands must hold before launch.
Last reviewed
2026-04-15
6 min
- RegulatorySG · MY · ID · TH · VN · PH
ASEAN Cosmetic Directive — what changed at the 39th and 40th meetings, and what it means for actives.
The 2026 ACD revisions tightened the actives lists across cosmetic notification regimes. A practical view of which ingredients now require dossier rework before regional launch.
Last reviewed
2026-04-15
7 min